LETM2 and glioblastoma: For example, CCDC8, CLDN1, JMJD8, PTRF, RNF135, and SNX21 in classical (Berezovsky et al., 2014; Karnati et al., 2014; Pangeni et al., 2015; Yeo et al., 2016; Huang et al., 2018; Zhang et al., 2019) (Figure 5A–F); GCNT1, RAB38, HLX, ZDHHC12, SRCRB4D (SSC4D), GNB2, and LETM2 in mesenchymal (Thaker et al., 2009; Chen et al., 2014; Toton et al., 2018; Chen et al., 2020; Bianchetti et al., 2021; Giambra et al., 2021; Katsushima et al., 2021) (Figure 5G–M); and TOLLIP and DUOX1 (Humbert-Claude et al., 2016; Little et al., 2016) in proneural (Figure 5N–O) are linked to GBM patient survival.